BiotechTube

AUTO3

Phase 1/2Terminated
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Conditions

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Trial Timeline

Sep 5, 2017 โ†’ Oct 19, 2023

NCT ID
NCT03287817

About AUTO3

AUTO3 is a phase 1/2 stage product being developed by Autolus Therapeutics for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). The current trial status is terminated. This product is registered under clinical trial identifier NCT03287817. Target conditions include Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT03287817Phase 1/2Terminated

Competing Products

20 competing products in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

See all competitors
ProductCompanyStageHype Score
agenT-797MiNK TherapeuticsPhase 1
25
Valemetostat TosylateDaiichi SankyoPhase 2
52
Eribulin mesylateEisaiPhase 2
52
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
77
Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + EpcoritamabEli LillyPhase 1/2
41
ISB 1342Glenmark PharmaceuticalsPhase 1
33
SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
77
Linperlisib ๏ผ› RituximabJiangsu Hengrui MedicinePhase 1/2
41
Epcoritamab + Epcoritamab, lenalidomide and rituximabAbbViePhase 2
52
EtentamigAbbViePhase 1
33
Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclaxAbbViePhase 3
77
Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + DaratumumabAbbViePhase 1
33
[14C]ABT-199 (GDC-0199)AbbViePhase 1
33
ABT-199 + bortezomib + dexamethasoneAbbViePhase 1
33
Venetoclax + DexamethasoneAbbViePhase 1/2
41
ABBV-453 + Dexamethasone + Daratumumab + LenalidomideAbbViePhase 1
33
mRNA-2752 + DurvalumabAstraZenecaPhase 1
33
AZD4573AstraZenecaPhase 2
52
Moxetumomab PasudotoxAstraZenecaPre-clinical
23
Administration of AZD6738AstraZenecaPhase 1
33

Other Products from Autolus Therapeutics

AUTO CAR T cell therapyPhase 2
44
Obecabtagene autoleucelPhase 2
44
Obecabtagene autoleucelPhase 2
44
Obecabtagene AutoleucelPhase 2
44
AUTO4Phase 1/2
33